SECOND AMENDMENT TO LICENSE AGREEMENT - ROLONTISLicense, Development and Supply Agreement - Rolontis • March 31st, 2023 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations
This SECOND AMENDMENT TO LICENSE, DEVELOPMENT AND SUPPLY AGREEMENT - ROLONTIS (this “Second Amendment”) is made and effective as of January 1st, 2022 (the “Second Amendment Effective Date”) by and between Spectrum Pharmaceuticals Inc., a Delaware corporation (“Spectrum”) and Hanmi Pharmaceuticals Co., Ltd., a company incorporated under the laws of the Republic of Korea (“Hanmi”). In this Second Amendment, Hanmi and Spectrum each may be referred to individually as a “Party” and together as the “Parties.”
